Partnership to Offer New Coagulation Testing Solutions Worldwide

Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in various regions, enabling Abbott to provide its coagulation testing solutions with the CP3000, expected to become available later in 2015 in Europe, countries that recognize CE-marking, and non-regulated countries, and in 2016 in the United States. Abbott will have non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan, and Macau.

CP3000 features small sample volume requirement, high-throughput, and a compact footprint. With a broad assay menu and rapid result turnaround time, CP3000 can rapidly meet workflow needs of laboratories of all sizes while providing high quality, reliable results. The system will aim to seamlessly connect to Abbott's “Accelerator a3600” lab automation platform and middleware solution.

"Abbott is committed to providing testing solutions that healthcare providers rely on for actionable information in diagnosing and treating various medical conditions," said Jaime Contreras, senior vice president, Commercial Operations, Diagnostics, Abbott, "Collaborating with Sekisui broadens our offerings within hematology, providing an important component needed to improve care for people around the world." Coagulation testing helps diagnosis blood-related disorders such as hemophilia and thrombosis, and helps clinicians assess patients prior to many medical treatments and in monitoring those who take medications that can affect clotting.

“Coagulation testing has been an important focus for Sekisui for over 20 years," said Robert Schruender, president and chief operating officer of Sekisui Diagnostics, "We are delighted that this relationship with Abbott will bring the benefits of our system, a leading product in Japan, to many customers around the world."

Related Links:
Abbott
Sekisui Diagnostics